Grown Rogue International (GRUSF) Cost of Revenue (2018 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Cost of Revenue of $5.2 million in Q1 2026, up 100.0% quarter-over-quarter from -$16499.5 billion in Q4 2025, and up 37.28% on a YoY basis from $3.8 million in Q1 2025.
Grown Rogue International (GRUSF) Cost of Revenue (2018 - 2026) Analysis & Trends
Grown Rogue International's Cost of Revenue history runs 9 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 37.28% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at -$2301499159.8 billion (down 13346812549744.62% YoY), while the FY2025 annual figure was $18.3 million, up 36.64% from the prior year.
- Cost of Revenue was $5.2 million for Q1 2026 at Grown Rogue International, up from -$16499.5 billion in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $1780.1 billion in Q3 2025 to a low of -$2301484440.5 billion in Q2 2025.
- Historically, Cost of Revenue has averaged -$153433277.3 billion across 5 years, with a median of $224636.0 in 2023.
- Biggest YoY gain for Cost of Revenue was 5170235979.08% in 2025; the steepest drop was 5278709936550273.0% in 2025.
- A 5-year view of Cost of Revenue shows it stood at $1.4 million in 2022, then sank by 93.72% to $89210.0 in 2023, then soared by 14897.59% to $13.4 million in 2024, then plunged by 123320544.61% to -$16499.5 billion in 2025, then soared by 100.0% to $5.2 million in 2026.
- The last three Cost of Revenue figures came in at $5.2 million (Q1 2026), -$16499.5 billion (Q4 2025), and $1780.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn | 5.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.20 Mn |
| Mar 31, 2026 | 5.20 Mn |
| Dec 31, 2025 | -16,499.47 Bn |
| Dec 31, 2025 | -16,499.47 Bn |
| Sep 30, 2025 | 1,780.12 Bn |
| Sep 30, 2025 | 1,780.12 Bn |
| Jun 30, 2025 | -2,301,484,440.47 Bn |
| Jun 30, 2025 | -2,301,484,440.47 Bn |
| Mar 31, 2025 | 3.79 Mn |
| Mar 31, 2025 | 3.79 Mn |
| Dec 31, 2024 | 13.38 Mn |
| Dec 31, 2024 | 13.38 Mn |
| Sep 30, 2024 | 34,430.05 |
| Sep 30, 2024 | 34,430.05 |
| Jun 30, 2024 | 43,599.37 |
| Jun 30, 2024 | 43,599.37 |
| Mar 31, 2024 | 100,069.00 |
| Mar 31, 2024 | 100,069.00 |
| Dec 31, 2023 | 89,210.00 |
| Dec 31, 2023 | 89,210.00 |